REPLIMUNE GROUP, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
REPLIMUNE GROUP, INC. (REPL) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$66.04 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-29.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-06-29
- REPLIMUNE GROUP, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2026 was -$66.04M.
- REPLIMUNE GROUP, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$25.87M.
- REPLIMUNE GROUP, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$19.37M.
- REPLIMUNE GROUP, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$18.37M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2026-03-31 | -$66.04M 10-K · filed 2026-06-29 |
| 2025-03-31 | -$25.87M 10-K · filed 2026-06-29 |
| 2024-03-31 | -$19.37M 10-K · filed 2025-05-22 |
| 2023-03-31 | -$18.37M 10-K · filed 2024-05-16 |
| 2022-03-31 | -$28.98M 10-K · filed 2023-05-18 |
| 2021-03-31 | -$22.77M 10-K · filed 2022-05-19 |
| 2020-03-31 | -$12.96M 10-K · filed 2021-05-20 |
| 2019-03-31 | -$9.48M 10-K · filed 2020-06-03 |
| 2018-03-31 | -$8.99M 10-K · filed 2020-06-03 |
| 2017-03-31 | -$3.45M 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |